AstraZeneca Pharma India Limited (ASTRAZEN) Fair Value & Analysis
Healthcare · IN · Market cap ₹211B (≈ $2.2B) · ISIN INE203A01020
What is AstraZeneca Pharma India Limited really worth?
A solid business, but trading 364% above our fair value of ₹1,495.
Strengths
Risks
For context
Fair value as of: Sep 2, 2026
From 25 valuation models · updated 2 days ago
Share price −14.4% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (₹2,068). The favourable scenario is already priced in.
- The model range is unusually wide (₹770.00 to ₹2,068). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 2, 2026.
How to read this chart
60‑month range ₹2,426 – ₹10,474 · fair‑value band ₹770.00 – ₹2,068 · the ₹6,944 price screens above the ₹1,495 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 2, 2026.
Analysis
AstraZeneca Pharma India Limited (ASTRAZEN) currently trades at ₹6,944, while our model-based Fair Value estimate is ₹1,495, implying the stock looks roughly 364.5% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of ₹1,848 per share, and 0 of the 25 models we run sit above the ₹6,944 price. Bear case: the Growth DCF group reads lowest at ₹220.27, and 25 of the 25 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, AstraZeneca Pharma India Limited generated revenue of ₹22.8B at a net margin of 8.2%. Revenue grew 20.4% year over year. It earns a return on equity of 22.8%. The balance sheet holds a net cash position of ₹3.4B. Fundamentals as of Sep 2, 2026
Our scenario range runs from ₹770.00 (bear case) to ₹2,068 (bull case); at ₹6,944, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −78%, ASTRAZEN screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2026 figures, and about 5 months have passed since. In that time the company retained roughly ₹16.64 per share, which is 1.1 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 25 models by family
Widest divergence: Growth Earnings (₹1,848) versus Growth DCF (₹220.27). Highest evidence: FCF DCF (80).
Notify me when ASTRAZEN reaches fair value
Put ASTRAZEN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 2, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 38
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally.
Full company description
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company has a strategic collaboration with Leica Biosystems and Daiichi Sankyo Company, Limited for the development of an immunohistochemistry assay and an image analysis algorithm for the TROP2 NMR biomarker in non-small cell lung cancer. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
AstraZeneca Pharma India Limited reported revenue of ₹22.8B in FY2026 versus ₹8.1B in FY2022, a compound +29.6%/yr. Reported net income was ₹1.9B in FY2026, compounding +32.1%/yr from FY2022.
ASTRAZEN screens 364% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Sep 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare AstraZeneca Pharma India Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is AstraZeneca Pharma India Limited (ASTRAZEN) overvalued or undervalued?
What is the fair value of ASTRAZEN?
What is the quality score of ASTRAZEN?
What is the revenue of AstraZeneca Pharma India Limited (ASTRAZEN)?
What is the net profit margin of ASTRAZEN?
Does AstraZeneca Pharma India Limited pay a dividend?
Watch AstraZeneca Pharma India Limited in the live analysis
One click puts AstraZeneca Pharma India Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.